Morla Báez E, Dorantes Alvarez L M, Chavarría Bonequi C
Bol Med Hosp Infant Mex. 1980 Nov-Dec;37(6):1103-11.
Commercial preparations of vasopressin for the treatment of diabetes insipidus are not available in Mexico. Besides, the hormone is useless in the nephrogenic variety. In the department of Endocrinology at the Hospital Infantil de Mexico, a preparation containing hydrochlorothiazide, aminopyrine and potassium chloride, which reduces urinary volumes in about two thirds, is employed in all varieties of the disease. Growth in stature was investigated in 44 patients under treatment, attending the Endocrine Outpatient Clinic since 1967 for a period of 2 to 12 years. Clinical material included 29 males and 15 females. There were 23 idiopathic, 7 histiocytosis, 5 nephrogenic, 4 craniopharyngiomas, 2 psychogenic polydipsia, 2 traumatic and 1, as a sequel of tuberculous meningoencephalitis. Six idiopathic, 2 nephrogenic, 2 traumatic, 1 histiocytosis, and 1 psychogenic proceeded between percentiles 3 and 97, parallel to the nearest line of reference along the whole period of study. Two nephrogenic, 2 histiocytosis, 1 psychogenic, 1 post-meningoencephalitis and 14 idiopathic, grew below the third percentile, but parallel to it. One nephrogenic, 4 histiocytosis, 4 craniopharyngioma and 3 idiopathic progressively departed from the initial centile. Two of the latter had growth hormone deficiency, and 1 had been very irregularly treated. It is concluded that the therapy employed limits stature impairment but does not produce catch-up growth. Accordingly, it is proposed that the treatment of diabetes insipidus should be started as early as possible, and that if progress in stature is appreciably deteriorated, the presence of additional pathology should be suspected.
墨西哥没有用于治疗尿崩症的加压素商业制剂。此外，该激素对肾性尿崩症无效。在墨西哥儿童医院内分泌科，一种含有氢氯噻嗪、氨基比林和氯化钾的制剂被用于治疗各种类型的尿崩症，它可使尿量减少约三分之二。对44例接受治疗的患者的身高增长情况进行了调查，这些患者自1967年起在内分泌门诊就诊，治疗时间为2至12年。临床资料包括29名男性和15名女性。其中有23例特发性尿崩症、7例组织细胞增多症、5例肾性尿崩症、4例颅咽管瘤、2例精神性多饮、2例创伤性尿崩症以及1例结核性脑膜脑炎后遗症。6例特发性、2例肾性、2例创伤性、1例组织细胞增多症和1例精神性尿崩症患者的身高在第3百分位和第97百分位之间，在整个研究期间与最近的参考线平行。2例肾性、2例组织细胞增多症、1例精神性、1例脑膜脑炎后和14例特发性尿崩症患者的身高低于第3百分位，但与之平行。1例肾性、4例组织细胞增多症、4例颅咽管瘤和3例特发性尿崩症患者的身高逐渐偏离初始百分位。后两者中有2例生长激素缺乏，1例治疗非常不规律。结论是，所采用的治疗方法限制了身高损害，但不会产生追赶生长。因此，建议尽早开始治疗尿崩症，如果身高进展明显恶化，应怀疑存在其他病理情况。
